Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Naohisa Kuriyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9668-0500; OpenAlex author ID A5015214616. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 1 paper

Papers 22

  1. Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy. Co-author DOI 10.1002/ags3.70186↗
  2. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… First author DOI 10.1007/s00423-025-03609-8↗
  3. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
  4. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… Last author DOI 10.1097/md.0000000000042441↗
  5. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
  6. Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A… Last author DOI 10.3390/cancers17061048↗
  7. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-inten… Co-author DOI 10.1371/journal.pone.0309834↗
  8. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  9. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Co-author DOI 10.1002/ags3.12545↗
  10. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  11. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  12. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  13. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Co-author DOI 10.1016/j.pan.2021.08.011↗
  14. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
  15. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
  16. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
  17. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
  18. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
  19. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
  20. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
  21. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Cli… Co-author DOI 10.1097/mpa.0000000000000597↗
  22. Spontaneous Rupture of an Intrasplenic Aneurysm After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jemermed.2014.11.025↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shugo Mizuno · 22 shared papers, 2015–2026 · strength 3.06
  2. Yasuhiro Murata · 21 shared papers, 2016–2026 · strength 3.01
  3. Masashi Kishiwada · 21 shared papers, 2016–2026 · strength 3.01
  4. Aoi Hayasaki · 20 shared papers, 2018–2026 · strength 2.97
  5. Takahiro Ito · 11 shared papers, 2018–2025 · strength 1.93
  6. Kazuyuki Gyoten · 11 shared papers, 2021–2025 · strength 1.78
  7. Shuji Isaji · 13 shared papers, 2015–2023 · strength 1.20
  8. Hiroyuki Sakurai · 12 shared papers, 2015–2022 · strength 1.16
  9. Benson Kaluba · 6 shared papers, 2022–2025 · strength 1.14
  10. Toru Shinkai · 5 shared papers, 2021–2025 · strength 0.80
  11. Hiroyuki Kato · 7 shared papers, 2018–2022 · strength 0.59
  12. Miki Usui · 2 shared papers, 2025–2026 · strength 0.49
  13. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  14. Takuya Yuge · 1 shared paper, 2024 · strength 0.20
  15. Masatoshi Watanabe · 1 shared paper, 2025 · strength 0.20
  16. Taijiro TAKEUCHI · 1 shared paper, 2019 · strength 0.08
  17. Warakorn Jaseanchiun · 1 shared paper, 2019 · strength 0.08
  18. Ken Ichikawa · 1 shared paper, 2019 · strength 0.08
  19. Hajime Sakuma · 1 shared paper, 2015 · strength 0.05
  20. Misao Yoneda · 1 shared paper, 2016 · strength 0.04
  21. Taizo Shiraishi · 1 shared paper, 2016 · strength 0.04
  22. Junya Tsuboi · 1 shared paper, 2016 · strength 0.04
  23. Hiroyuki Inoue · 1 shared paper, 2016 · strength 0.04
  24. Kazuki Kanayama · 1 shared paper, 2016 · strength 0.04
  25. Reiko Yamada · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.